Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

Annual screening tests do not decrease deaths from prostate cancer

There's new evidence that annual prostate cancer screening does not reduce deaths from the disease, even among men in their 50s and 60s and those with underlying health conditions, according to new research led by Washington University School of Medicine in St. Louis.

6 Jan 2012

State roundup: Colo. reports 'record' number of Medicaid recipients; Hollywood nursing home stymied by Congress?

Nearly 615,000 Coloradans were on Medicaid in November, by far a record high, officials said Wednesday, attributing the vast bulk of the growth to economic hard times rather than recent eligibility expansions. ... the 614,146 Coloradans enrolled in Medicaid in November represented a 57.7 percent increase over January 2007. ... roughly 13 percent of all Coloradans are covered by state health-insurance programs.

6 Jan 2012

Experts share 10 symptoms of cervical and other gynecologic cancers

Pelvic pain and abnormal bleeding aren't the only signs of gynecologic cancer. As part of Cervical Health Awareness Month in January, experts at The University of Texas MD Anderson Cancer Center share other symptoms that often are overlooked.

6 Jan 2012

New anti-tumor compounds show promise for hard-to-treat cancers

New anti-tumor compounds produced by Dr. Aleem Gangjee, Distinguished Professor of Medicinal Pharmacy at Duquesne University's Mylan School of Pharmacy, show such promise for fighting hard-to-treat tumors that the National Institutes of Health (NIH) has placed them on its fast track for development.

6 Jan 2012

New algorithm could help GPs identify women at risk of early ovarian cancer

The lives of hundreds of women could be saved every year, thanks to a simple online calculator that could help GPs identify women most at risk of having ovarian cancer at a much earlier stage.

5 Jan 2012

Avastin fails to live up to expectations for extending survival in ovarian cancer

Cancer drug Avastin has been found to add about four months to the time it takes for the cancer to worsen for women with advanced cases of ovarian cancer says a new report. However it may not extend survival significantly.

29 Dec 2011

GOG targeted therapy phase 3 clinical trial delays progression of advanced ovarian cancer

Targeted drugs, which block or disrupt particular molecules involved in the growth of tumors, have been shown to be effective treatments against many types of cancer.

29 Dec 2011

Bevacizumab delays disease progression in ovarian cancer

Treating ovarian cancer with the drug bevacizumab ("Avastin") delays the disease and may also improve survival, show the results of an international clinical trial co-led by Drs. Amit Oza of the Princess Margaret Cancer Program, University Health Network and Timothy Perren, St James's Institute of Oncology, Leeds, UK.

29 Dec 2011

Women with breast cancer more likely to develop heart disease

Women who are at risk for breast cancer may also be at greater risk for heart disease, new research has found.

21 Dec 2011

Newgen acquires novel oncology development programs from Kanion

NewGen Therapeutics, Inc. today announced the acquisition of three novel oncology development programs from Kanion USA, Inc. and Kanion Pharmaceutical Co., Ltd..

19 Dec 2011

Scientists devise a way to reduce side effects of lung cancer therapy

Scientists may have a way to double the efficacy and reduce the side effects of radiation therapy.

17 Dec 2011

Cancer-causing potential of fetal exposure to carcinogens can vary substantially

The cancer-causing potential of fetal exposure to carcinogens can vary substantially, a recent study suggests, causing different types of problems much later in life depending on the stage of pregnancy when the fetus is exposed.

16 Dec 2011

Gynaecological cancer survival rates have improved in Eastern England

Gynaecological cancer survival rates have improved in Eastern England following the reorganisation of services and multidisciplinary team working finds a new study published in the gynaecological oncology themed issue of BJOG: An International Journal of Obstetrics and Gynaecology.

15 Dec 2011

Onconova announces data from five rigosertib clinical trials on MDS

Onconova Therapeutics announces three presentations relating to clinical trials of its Phase III-stage anticancer agent, rigosertib sodium (Estybon or ON 01910.Na), at the 53rd American Society of Hematology (ASH) Annual Meeting in San Diego, CA, December 10-13, 2011.

12 Dec 2011

Ovary removal in younger women may lead to low-bone mineral density, arthritis

Having both ovaries removed before age 45 is strongly associated with low-bone mineral density and arthritis in later years, according to a new study by Johns Hopkins oncologists and epidemiologists. The analysis covered several thousand women who took part in a U.S. government-sponsored, multiyear national health study, and excluded women whose ovaries were removed due to cancer.

9 Dec 2011

Ixabepilone-sunitinib combination holds potential against chemotherapy-resistant ovarian cancer

The use of two drugs never tried in combination before in ovarian cancer resulted in a 70 percent destruction of cancer cells already resistant to commonly used chemotherapy agents, say researchers at Mayo Clinic in Florida.

8 Dec 2011

Genetic variation predicts survival chances of ovarian cancer

Yale Cancer Center researchers have shown that a tiny genetic variation predicts chances of survival and response to treatment for patients with ovarian cancer.

5 Dec 2011

P-Rex1 gene plays a key role in the spread of malignant melanoma

SCIENTISTS in Glasgow have made an important discovery in the fight against malignant melanoma, the most dangerous form of skin cancer.

5 Dec 2011

Advaxis completes ADXS-HER2 pre-IND meeting with FDA

Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, completed a pre-IND meeting with the FDA on November 22, 2011 to discuss the development plan for ADXS-HER2, an immunotherapy for the treatment of HER2 expressing cancers.

23 Nov 2011

Study reveals PEA-15 protein can enhance cancer cell proliferation

A new study from the University of Hawaii Cancer Center reveals that PEA-15, a protein previously shown to slow ovarian tumor growth and metastasis, can alternatively enhance tumor formation in kidney cells carrying a mutation in a cancer-promoting gene called H-Ras.

22 Nov 2011